Status:
COMPLETED
MRA and ABR as Early Predictors of Bilirubin-Induced Neurologic Dysfunction in Full-term Jaundiced Neonates
Lead Sponsor:
Tanta University
Conditions:
Neonatal Hyperbilirubinemia
Eligibility:
All Genders
1-28 years
Brief Summary
The aim of the research was to define the role of MRS and ABR as early predictors of bilirubin-induced neurologic dysfunction (BIND) in full-term neonates who required intervention (phototherapy or ex...
Detailed Description
Neonatal jaundice is a prevalent condition. It's typically a harmless phase that occurs as the body adjusts to bilirubin levels after birth, representing a balance between its production and eliminati...
Eligibility Criteria
Inclusion
- This study included term, appropriate for gestational age (AGA) neonates with pathological unconjugated hyperbilirubinemia who were candidates for intervention (Intensive phototherapy versus Exchange transfusion) using the American Academy of Pediatrics guidelines; 2004.
Exclusion
- Preterm neonates (less than 37 weeks).
- Clinically moderate and severe acute bilirubin encephalopathy according to modified Bilirubin-induced neurologic dysfunction (BIND-M) score.
- Neonates born with birth asphyxia and/or poor Apgar score.
- Neonates with sepsis including CNS infection.
- Neonates with family history of childhood hearing loss.
- Congenital infection.
- Chromosomal abnormalities.
- Congenital ear anomalies associated with hearing loss or brain abnormalities including craniofacial anomalies.
- Patients who were receiving ototoxic drugs as aminoglycosides.
- Conjugated hyperbilirubinemia.
Key Trial Info
Start Date :
March 1 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 1 2021
Estimated Enrollment :
76 Patients enrolled
Trial Details
Trial ID
NCT06018012
Start Date
March 1 2019
End Date
April 1 2021
Last Update
September 1 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
faculty of medicine,Tanta University
Tanta, Q2x2+cp Tanta 2, Egypt, 31527